Pacira BioSciences, Inc.· PCRX
🇺🇸 US · SmallSP600NASDAQ
- Price
- $27.62
- Day
- +2.60%
- Mkt Cap
- $1.09B
- 52W Range
- $18.80 – $27.66
- Volume
- 1.10M
- Beta
- 0.27
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
Read full article
-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif.
Read full article
Pacira (PCRX) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.74 per share a year ago.
Read full article
First Trust Advisors LP boosted its stake in Pacira BioSciences, Inc. (NASDAQ: PCRX) by 59.2% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 300,632 shares of the company's stock after purchasing an additional 111,743 shares during the period. First Trust Advisors LP owned about 0.76%
Read full article
— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process — — Topline data from Part A of Phase 2 ASCEND study remains on track for end of year — BRISBANE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has successfully transitioned PCRX-201 (enekinragene inzadenovec), its investigational locally administered gene therapy for osteoarthritis of the knee, to a U.S.-based scalable commercial manufacturing process intended to support future registrational development and commercialization.
Read full article
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) have been assigned an average recommendation of "Hold" from the seven brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have assigned a buy recommendation to the
Read full article
BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter 2026 financial results after the close of the U.S. markets on Tuesday August 4, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
Read full article